2 transcripts
LCTX
Earnings call transcript
NYSEAMERICAN
2024 Q1
9 May 24
50% with the resources that a Genentech can put into this program or a Roche can put into this program.
So we still are a minority in terms
LCTX
Earnings call transcript
NYSEAMERICAN
2023 Q4
7 Mar 24
history of these patients, have they not gotten OpRegen? And what are -- would you say are factors that have contributed to these, I'd call it, minor
- Prev
- 1
- Next